NCT01488461

Brief Summary

Congenital ataxias (CA) are rare, non progressive diseases, characterized by psychomotor retardation, hypotonia followed by ataxia. The presence of the "molar tooth" on MRI allowed to define Joubert syndrome, a peculiar form of CA. Apart from this group, CA are mostly associated with cerebellar atrophy or hypoplasia without molar tooth on MRI. CA are a clinically as well as genetically heterogeneous group of diseases. Early-onset ataxias are progressive but may be difficult to distinguish from CA in the first years of the disease. To date, few genes responsible for CA have been identified: ABC7 (X-linked CA associated with sideroblastic anemia), SLC9A6 (X-linked CA associated with severe mental retardation, autism and epilepsy), GPR56 (CA associated with polymicrogyria), ATCAY (pure CA in Cayman isolate); the involvement of the ATCAY and ABC7 genes has never been assessed in a large cohort of CA patients. Primary objective: To assess the frequency of mutations of the ATCAY and ABC7 genes in patients affected with non Joubert congenital or early-onset ataxia. Secondary objective: To identify new loci and/or genes responsible for CA To further describe the clinical phenotype of the CA and to assess the frequency of the various clinical types (pure CA/CA associated with spasticity/ syndromic CA, congenital/early-onset CA, sporadic/familial CA). To describe the clinical phenotype of CA related to mutations in one of analysed genes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
165

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 6, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 8, 2011

Completed
24 days until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

June 15, 2015

Status Verified

June 1, 2015

Enrollment Period

2.8 years

First QC Date

December 6, 2011

Last Update Submit

June 12, 2015

Conditions

Keywords

Congenital cerebellar ataxiasGeneticsGene ATCAYGene ABC7Cerebellar atrophy

Outcome Measures

Primary Outcomes (1)

  • Percentage of the patients with a mutation in one of the analysed genes.

    1 day

Secondary Outcomes (2)

  • Percentage of patients with severe/moderate/mild/absent intellectual deficiency

    1 day

  • Percentage of patients with/without epilepsy/spasticity/extraneurological features and nature and frequency of MRI anomalies

    1 day

Study Arms (1)

patients ataxic

Genetic: blood sample

Interventions

Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.

patients ataxic

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All types

You may qualify if:

  • Patient, child or adult, affected with a congenital or early-onset ataxia defined by:
  • Neurological symptoms observed before age of 2 years.
  • Non progressive cerebellar ataxia observed at the time of examination. Karyotype done or in progress

You may not qualify if:

  • Metabolic disease
  • Specific MRI malformations suggesting a peculiar entity : molar tooth (joubert syndrome), superior vermis dysplasia with cleft (Oligophrenin)
  • Muscle weakness and elevated creatine phosphokinase (CPK)
  • Clearly progressive ataxia.
  • Absence of signature of the informed consent.
  • Absence of affiliation to social security

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Trousseau, Service de Génétique

Paris, 75012, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Lydie Burglen, PhD

    Assistance Publique

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2011

First Posted

December 8, 2011

Study Start

January 1, 2012

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

June 15, 2015

Record last verified: 2015-06

Locations